Previous Close | 121.25 |
1-Year Change | 121.91% |
6-Months Change | 38.92% |
3-Months Change | 21.74% |
Moving Avg (50d) | 105.57 |
Moving Avg (200d) | 89.28 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 2.19B |
Beta (3-Years) | 1.07 |
Revenue Growth (ttm) | -25.82% |
Net Profit Margin (ttm) | 31.57% |
Return On Assets (ttm) | 4.86% |
EPS (ttm) | 2.31 |
PE Ratio (ttm) | 52.49 |
Dividend Yield | % |
Asset Description: | Ligand Pharmaceuticals Incorporated |
Predicted Direction: | Buy |
Signal Strength: | Buy |
Forecast Date: | 2024-11-04 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
118.825 | 115.188 | 112.763 | 109.125 | 103.063 | 97 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.